Cyclo Therapeutics, Inc. (CYTH) Reports Q3 Loss, Lags Revenue Estimates
Portfolio Pulse from
Cyclo Therapeutics, Inc. (CYTH) reported a Q3 loss of $0.26 per share, missing the Zacks Consensus Estimate of a $0.17 loss. This is an improvement from the $0.29 loss per share a year ago.
November 14, 2024 | 1:30 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Cyclo Therapeutics reported a Q3 loss of $0.26 per share, missing the expected $0.17 loss. This is a slight improvement from last year's $0.29 loss.
The reported loss per share of $0.26 is worse than the expected $0.17 loss, which is likely to negatively impact the stock price in the short term. However, the loss is an improvement from the previous year's $0.29, which may mitigate some negative sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100